Do the right thing . . . Right!

"Genetic Networks' innovative GeneScape platform produces powerful, unbiased scientific evidence that has opened up new target identification and cellular connectivity with existing drugs and drug candidates that previously had been unknown.”

WILLIAM A. LEE

EVP, Research, Gilead Sciences

 

Three Top-Ten biopharmas are already leveraging our GeneScape platform:

 

Prioritizing assets for development or acquisition

Optimizing existing assets across all stages of development

Predicting new combinatorial assets

Identifying clinical diagnostics for optimization

Screen Shot 2020-08-03 at 12.36.39 PM.png
 

GeneScape, our proprietary platform, is powered by:

 

10k Drug Response Matrices involving 30M chemo-genomic interactions (H-Tech)

5k Gene Response Matrices involving 25M tested genetic interactions (Y-Tech)

5k human diseases and phenotypes involving 125k genotype-disease relationships (Analytics)

Our COVID-19 Initiative

 

At the beginning of the SARS-CoV-2 pandemic, Genetic Networks mobilized our Sentinel Paradigm Platform powered by GeneScape to identify existing drugs and compounds in development that could be quickly repurposed for treatment of COVID-19.

In less than one month, Genetic Networks identified thirteen drugs / compounds for rapid in vitro testing. Ten of the thirteen were found to have antiviral activity against SARS-CoV2. Remarkably, five of the drugs are now in clinical trials for COVID-19.

To reduce mortality and long-term effects of SARS-CoV2 infection, Genetic Networks is currently working to put these host-directed anti-infective compounds into clinical trials.

 
COVID-19 Response.jpg